The AmoyDx® HANDLE Melanoma NGS Panel is a Next-Generation Sequencing-based assay for the qualitative detection of SNVs and InDels in nine key melanoma genes.
Analyzing DNA from FFPE tissue with the AmoyDx® HANDLE Melanoma NGS Panel not only allows the analysis of common biomarkers, such as BRAF, but also the detection of mutations in two critical hotspot areas of the TERT promoter. On top of that, the fast and flexible HANDLE technology allows library preparation in only 5 hours with only one reaction tube per sample.
For more information about the AmoyDx® HANDLE Melanoma NGS Panel click here.
This product is for research use only (RUO).
Breast cancer is one of the most common cancers in women worldwide. In Germany, every 8th woman is diagnosed with breast cancer. Until now, therapies have been based on the presence/absence of (hormone) receptors or the Her2 receptor in metastatic/non-metastatic breast cancer.
Today, we are proud to announce that ZytoVision, our sister company, received the IVDR certification!